Resources Publications, Posters, Webinars, Videos and Brochures


Publication

#publication | Jan. 2020

Galon J & Bruni D

Tumor Immunology and Tumor Evolution: Intertwined Histories

Immunity

Poster

#poster | Dec. 2019

Poster presented at SITC 2019

Immunogram to decipher PD1/L1 ICI resistance: a proof of concept in advanced Non-small cell lung cancer patients of the PIONeeR Project.

Brochure

#brochure | Dec. 2019

Brochure Immunoscore® in Localized Colon Cancer

For Patients & Caregivers (Spanish)

Brochure

#brochure | Dec. 2019

Brochure Immunoscore® in Localized Colon Cancer

For Healthcare Professionals (CE/IVD version)

Brochure

#brochure | Dec. 2019

Brochure Immunoscore® in Localized Colon Cancer

For Healthcare Professionals (CLIA US version)

Brochure

#brochure | Dec. 2019

Brochure Immunoscore® in Localized Colon Cancer

For Patients & Caregivers (English)

Poster

#poster | Nov. 2019

Poster presented at ESMO 2019 by Transgene

In the Phase Ib/II trial of TG4001, HalioDx Immunoscore®, Immunosign® and others clinical research service have been performed to assess Immune contexture of patients.

Poster

#poster | Nov. 2019

Poster presented at SITC 2019

Tumor Infiltrating Lymphocytes (TILs) in triple-negative breast cancer: High Immunoscore is associated with pathological CR in patients receiving neoadjuvant chemotherapy.

Poster

#poster | Nov. 2019

Poster presented at ESMO 2019

High Immunoscore® is associated with good response to neo-adjuvant chemotherapy and prolonged survival in advanced Head and Neck cancer patients.

Poster

#poster | Nov. 2019

Poster presented at SITC 2019

Unveilling tumor-associated macrophages (TAMs) heterogeneity and plasticity by a fully automated sequential chromogenic multiplex assay.

Poster

#poster | Nov. 2019

Poster presented at SITC 2019

Cancer Immunogram: combining multi-parameter approach and machine learning to capture the complexity of tumor immune contexture.

Brochure

#brochure | Oct. 2019

Brochure IVD Development

HalioDx provides flexible services for IVD assay development for companies in the diagnostics and pharma industries, for technology providers and for clinical labs.

Video

#video | Sep. 2019

Webinar Immunoscore®: IDEA France study results in Stage III Colon Cancer - Sept. 19, 2019 | Franck Pagès, Eric Van Cutsem
Publication

#publication | Aug. 2019

Angell HK, Bruni D, Barrett JC et al.

The Immunoscore: Colon Cancer and Beyond.

Clin Cancer Res.

Poster

#poster | Jul. 2019

Poster presented at ESMO GI 2019

Significant differences in outcome between Immunoscore categories in stage I colon cancer patients

Publication

#publication | Jul. 2019

Mascaux C, Angelova M, Vasaturo A et al.

Immune evasion before tumour invasion in early lung squamous carcinogenesis.

Nature

Video

#video | Jul. 2019

HalioDX is part of the COLOSSUS project by performing Immunoscore and help stratification of difficult to treat mCRC patients with a final objective to Improve their management and treatment
Video

#video | Jun. 2019

Extract of an interview by Cancer.fr of Professor Thierry André, on Immunoscore® in the IDEA France study (in French)
Video

#video | Jun. 2019

Jérôme Galon, winner for the European Inventor Award 2019 for Immunoscore®
Poster

#poster | Jun. 2019

Poster presented at ASCO 2019

Validation of the Immunoscore Prognostic Value in Stage III Colon Cancer Patients treated with Oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR).

Video

#video | May. 2019

Discover HalioDx - Reportage by Grand Luminy Technopole - April 2017
Video

#video | Apr. 2019

Immunogram Clinical Seminar (Atlanta, April 2019) | Jérôme Galon, PhD
Video

#video | Apr. 2019

Immunogram Clinical Seminar (Atlanta, April 2019) | Jacques Fieschi, PhD
Video

#video | Apr. 2019

Dr. Fakih Discusses the Utility of Immunoscore® in CRC
Poster

#poster | Apr. 2019

Poster presented at AACR 2019

Combining multimodal biomarkers as an immunogram to guide immunotherapy use: A Proof of Concept

Poster

#poster | Apr. 2019

Poster presented at AACR 2019 by Lytix biopharma

A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefits in patients with advanced sarcoma

Poster

#poster | Apr. 2019

Poster presented at AACR 2019 by Lytix biopharma

A phase I study of the oncolytic peptide LTX-315 generates de novo T-cell responses and clinical benefit in patients with advanced melanoma

Poster

#poster | Apr. 2019

Poster presented at AACR 2019

Validation of Brightplex®, a multiplex IHC solution for immune cell phenotyping of the tumor microenvironment

Video

#video | Mar. 2019

Immunoscore® Webinar New data in Stage II Colon Cancer - March 21, 2019 | Jêrome Galon, PhD
Publication

#publication | Mar. 2019

Zeitoun G, Sissy CE, Kirilovsky A et al.

The Immunoscore in the Clinical Practice of Patients with Colon and Rectal Cancers.

Chirurgia (Bucur).

Brochure

#brochure | Mar. 2019

Brochure Clinical Research

HalioDx Biopharma Services

Publication

#publication | Mar. 2019

Galon J & Bruni D

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.

Nat Rev Drug Discov.

Video

#video | Jan. 2019

Discover how Immunoscore® is predicting the risk of relapse in localized colon cancer in a short video
Poster

#poster | Jan. 2019

Poster presented at Gastrointestinal Cancers Symposium 2019

Immunoscore clinical utility to identify good prognostic Colon Cancer Stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided

Poster

#poster | Dec. 2018

Poster presented at ESMO ASIA 2018

UCGI 34 - PROSCORE: A prospective study assessing whether Immunoscore® test impacts the choice of adjuvant chemotherapy, in a multidisciplinary meeting, for treating non-metastatic colon cancer patients after curative-intent surgery

Poster

#poster | Dec. 2018

Poster presented at ESMO IO 2018

MSI status plus Immunoscore to select metastatic colorectal cancer patients for immunotherapies

Poster

#poster | Nov. 2018

Poster presented at ESMO ASIA 2018

Immunoscore feasibility study in routine postsurgical pathologic review for early‐stage colon cancer (CC) cases risk‐assessment

Poster

#poster | Nov. 2018

Poster presented at SITC 2018

Myeloid-derived suppressor cells (MDSC) assessment using an automated sequential chromogenic multiplex assay (Brightplex®)

Publication

#publication | Oct. 2018

Angelova M, Mlecnik B, Vasaturo A et al.

Evolution of Metastases in Space and Time under Immune Selection.

Cell

Poster

#poster | Oct. 2018

Poster presented at the CRI-CIMT-EATI-AACR 2018

T cell exhaustion assessment using an automated sequential chromogenic multiplex assay (Brightplex®)

Video

#video | Aug. 2018

Webinar on “Clinical utility of Immunoscore® in colon cancer” with Marc Van Den Eynde, MD, PhD | October 17, 2017
Video

#video | Aug. 2018

Dr Jerome Galon on the Prognostic Value of Immunoscore, Onclive - ASCO 2016
Video

#video | Aug. 2018

Immunoscore® Colon Symposium - June 1, 2018, Chicago | Discussion on clinical cases
Video

#video | Aug. 2018

Immunoscore® Colon Symposium - June 1, 2018, Chicago | Jérôme Galon, PhD
Video

#video | Aug. 2018

Immunoscore® Colon Symposium - June 1, 2018, Chicago | Stanley Hamilton, MD
Poster

#poster | Jun. 2018

Poster presented at ASCO 2018 by Lytix biopharma

A Phase I/II study of the oncolytic peptide LTX-315 combined with checkpoint inhibition generates de novo T-cell responses and clinical benefit in patients with advanced solid tumors

Publication

#publication | May. 2018

Pagès F, Mlecnik B, Marliot F et al.

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.

Lancet

Poster

#poster | Apr. 2018

Poster presented at AACR 2018

Multi-centric PD-L1 and CD8 IHC assessment in NSCLC using IMMUNOSCORE® IC previously Halioseek®) CE-IVD assay

Poster

#poster | Feb. 2018

Poster presented at ASCO GI 2018

Immunoscore provides prognostic information in low (T3N1) and high (T4 or N2) risk subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial [NCCTG N0147 (Alliance)

Publication

#publication | Feb. 2018

Sinicrope F, Shi Q, Hermitte F et al.

Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).

J Clin Oncol.

Publication

#publication | Jan. 2018

Mlecnik B, Van den Eynde M, Bindea G et al.

Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival.

J Natl Cancer Inst.

Publication

#publication | Dec. 2017

Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G

The immune contexture in cancer prognosis and treatment.

Nat Rev Clin Oncol.

Poster

#poster | Nov. 2017

Poster presented at SITC 2017 by Lytix biopharma

LTX-315, a first in class oncolytic peptide, reshapes the tumor microenvironment in the patients with advanced metastatic tumors: Results from an ongoing study

Poster

#poster | Nov. 2017

Poster presented at SITC 2017

Immunoscore IC (previously Halioseek® PD‐L1/CD8), a dual CD8 and PD‐L1 IVD assay to improve NSCLC patients stratification

Poster

#poster | Sep. 2017

Poster presented at NSH 2017

A multiplex immunohistochemistry assay for immune cells profiling on whole FFPE tumor tissue sections

Poster

#poster | Jun. 2017

Poster presented at ASCO 2017

Prognostic utility of immune markers and validation of Immunoscore® in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial [NCCTG N0147 (Alliance)]

Poster

#poster | Jun. 2017

Poster presented at ASCO 2017 by Lytix biopharma

LTX-315, a first in class oncolytic peptide reshapes the tumor microenvironment inducing a local and systemic effect in metastatic tumors: Results from an ongoing study

Publication

#publication | May. 2017

Sinicrope F, Shi Q, Hermitte F et al.

Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance).

J Clin Oncol.

Publication

#publication | May. 2017

Galon J, Mlecnik B, Marliot F et al.

Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.

J Clin Oncol.

Poster

#poster | Apr. 2017

Poster presented at AACR 2017

A new standardized CD8 and PD-L1 dual assay

Poster

#poster | Nov. 2016

Poster presented at SITC 2016

Immunoscore® analytical performance

Publication

#publication | Sep. 2016

Hermitte F

Biomarkers immune monitoring technology primer: Immunoscore® Colon.

Journal for ImmunoTherapy of Cancer

Publication

#publication | Aug. 2016

Kirilovsky A, Marliot F, El Sissy C et al.

Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients.

Int Immunol.

Publication

#publication | Mar. 2016

Mlecnik B, Bindea G, Angell HK et al.

Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.

Immunity

Publication

#publication | Feb. 2016

Mlecnik B, Bindea G, Kirilovsky A et al.

The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis.

Sci Transl Med.

Publication

#publication | Jun. 2015

Berghoff AS, Fuchs E, Ricken G et al.

Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.

Oncoimmunology

Publication

#publication | Oct. 2013

Bindea G, Mlecnik B, Tosolini M et al.

Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.

Immunity

Publication

#publication | Jul. 2013

Galon J, Angell HK, Bedognetti D, Marincola FM

The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.

Immunity

Publication

#publication | Mar. 2012

Fridman WH, Pagès F, Sautès-Fridman C, Galon J.

The immune contexture in human tumours: impact on clinical outcome.

Nat Rev Cancer.

Publication

#publication | Feb. 2011

Mlecnik B, Tosolini M, Kirilovsky A et al.

Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction.

J Clin Oncol.

Publication

#publication | Sep. 2006

Galon J, Costes A, Sanchez-Cabo F et al.

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

Science